Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $17.63 and traded as high as $18.74. Theravance Biopharma shares last traded at $18.15, with a volume of 548,170 shares changing hands.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several research reports. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. HC Wainwright increased their target price on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. B. Riley assumed coverage on Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $27.80.

Theravance Biopharma Trading Down 3.0%

The company has a 50-day moving average of $17.63 and a 200-day moving average of $14.43. The company has a market capitalization of $919.66 million, a price-to-earnings ratio of 31.84 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The business had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. On average, research analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the transaction, the senior vice president owned 277,695 shares in the company, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in Theravance Biopharma in the 3rd quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Theravance Biopharma during the third quarter worth about $101,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.